[
  {
    "ts": null,
    "headline": "Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off",
    "summary": "Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.",
    "url": "https://finnhub.io/api/news?id=4a248af94b0cc78aeff34580666ce67bd967c057c00af6d2f8228b16fb749953",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746122869,
      "headline": "Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off",
      "id": 134185569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.",
      "url": "https://finnhub.io/api/news?id=4a248af94b0cc78aeff34580666ce67bd967c057c00af6d2f8228b16fb749953"
    }
  },
  {
    "ts": null,
    "headline": "Biogen (NasdaqGS:BIIB) Reports Q1 Revenue Growth Despite Decline in Net Income",
    "summary": "Biogen (NasdaqGS:BIIB) reported a mixed financial performance with Q1 2025 earnings illustrating a decline in net income and EPS compared to the prior year, while revenue saw an increase. This week's share price move of 1.31% likely mirrored broader market trends, as major indexes rose with investor confidence buoyed by strong earnings reports from technology firms. The mixed results from Biogen would have added complexity to its performance amid a positive market backdrop, but not diverge...",
    "url": "https://finnhub.io/api/news?id=4b7831e1da55686da26245f432acc54c7492ed5170da956a76c41aaa303dd9c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746120907,
      "headline": "Biogen (NasdaqGS:BIIB) Reports Q1 Revenue Growth Despite Decline in Net Income",
      "id": 134185570,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (NasdaqGS:BIIB) reported a mixed financial performance with Q1 2025 earnings illustrating a decline in net income and EPS compared to the prior year, while revenue saw an increase. This week's share price move of 1.31% likely mirrored broader market trends, as major indexes rose with investor confidence buoyed by strong earnings reports from technology firms. The mixed results from Biogen would have added complexity to its performance amid a positive market backdrop, but not diverge...",
      "url": "https://finnhub.io/api/news?id=4b7831e1da55686da26245f432acc54c7492ed5170da956a76c41aaa303dd9c8"
    }
  },
  {
    "ts": null,
    "headline": "BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut",
    "summary": "Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year.",
    "url": "https://finnhub.io/api/news?id=e2b3d48a1ebddff360d57d4d3923a8d30fb55b166c7b873bb437e8a749818df2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746117840,
      "headline": "BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut",
      "id": 134185571,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year.",
      "url": "https://finnhub.io/api/news?id=e2b3d48a1ebddff360d57d4d3923a8d30fb55b166c7b873bb437e8a749818df2"
    }
  },
  {
    "ts": null,
    "headline": "Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "summary": "Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://finnhub.io/api/news?id=d28d15ee3543c05313fccced8e705e7c716a3bf4e49c10a269ab79d8b8b1a234",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746106234,
      "headline": "Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates",
      "id": 134174190,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
      "url": "https://finnhub.io/api/news?id=d28d15ee3543c05313fccced8e705e7c716a3bf4e49c10a269ab79d8b8b1a234"
    }
  },
  {
    "ts": null,
    "headline": "Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat?",
    "summary": "Biogen stock traded sideways Thursday after the company beat first-quarter expectations, including strong sales for two newcomer drugs.",
    "url": "https://finnhub.io/api/news?id=eb6e68a2a05e9803f3e8735ed263d21a34f576591c9be286324c1297b535afd3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746106094,
      "headline": "Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat?",
      "id": 134174191,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen stock traded sideways Thursday after the company beat first-quarter expectations, including strong sales for two newcomer drugs.",
      "url": "https://finnhub.io/api/news?id=eb6e68a2a05e9803f3e8735ed263d21a34f576591c9be286324c1297b535afd3"
    }
  },
  {
    "ts": null,
    "headline": "Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets",
    "summary": "Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was 1% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=b208c788571192d005abd023059ebe86412ce4f392390c2f60f16617b2f26020",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746105765,
      "headline": "Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets",
      "id": 134174192,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was 1% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=b208c788571192d005abd023059ebe86412ce4f392390c2f60f16617b2f26020"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. (BIIB) Q1 Earnings Lag Estimates",
    "summary": "Biogen (BIIB) delivered earnings and revenue surprises of -7.36% and 8.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=7255f8bddd7a5917e7e01fae044878be62cc33fa3085f5289ee35e4fcee1a35d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746101105,
      "headline": "Biogen Inc. (BIIB) Q1 Earnings Lag Estimates",
      "id": 134174193,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (BIIB) delivered earnings and revenue surprises of -7.36% and 8.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=7255f8bddd7a5917e7e01fae044878be62cc33fa3085f5289ee35e4fcee1a35d"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript",
    "summary": "Biogen Inc. (NASDAQ:BIIB) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsTim Power - Head, Investor RelationsChris Viehbacher -...",
    "url": "https://finnhub.io/api/news?id=b2fecc7cd0d6d42f570b23b6ce510a3dfcc073901767610f14979c30c1c53253",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746099503,
      "headline": "Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript",
      "id": 134172814,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Biogen Inc. (NASDAQ:BIIB) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsTim Power - Head, Investor RelationsChris Viehbacher -...",
      "url": "https://finnhub.io/api/news?id=b2fecc7cd0d6d42f570b23b6ce510a3dfcc073901767610f14979c30c1c53253"
    }
  },
  {
    "ts": null,
    "headline": "Biogen's results beat estimates on strength in rare disease drugs",
    "summary": "Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis medicines.  The drugmaker has focused on deals, cost-cutting measures and newer drugs to address investor pressure for growth as demand falls for its once top-selling multiple sclerosis medicines in the face of stiff competition in a crowded treatment market.  The \"relatively calm quarter\" for Biogen showed positive signs of improvement, said BMO Capital Markets analysts.",
    "url": "https://finnhub.io/api/news?id=802125be565922c378d99b8fd2f2430dce4b0a40599a4e8ae7d2e7f23b3bbbbe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746096524,
      "headline": "Biogen's results beat estimates on strength in rare disease drugs",
      "id": 134174194,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis medicines.  The drugmaker has focused on deals, cost-cutting measures and newer drugs to address investor pressure for growth as demand falls for its once top-selling multiple sclerosis medicines in the face of stiff competition in a crowded treatment market.  The \"relatively calm quarter\" for Biogen showed positive signs of improvement, said BMO Capital Markets analysts.",
      "url": "https://finnhub.io/api/news?id=802125be565922c378d99b8fd2f2430dce4b0a40599a4e8ae7d2e7f23b3bbbbe"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. 2025 Q1 - Results - Earnings Call Presentation",
    "summary": "The following slide deck was published by Biogen Inc.",
    "url": "https://finnhub.io/api/news?id=999d8e556cfc0a3b4d5f1112f0f51fa93ff02a792c65a44df7b6dad17bd51f26",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746088643,
      "headline": "Biogen Inc. 2025 Q1 - Results - Earnings Call Presentation",
      "id": 134171490,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "The following slide deck was published by Biogen Inc.",
      "url": "https://finnhub.io/api/news?id=999d8e556cfc0a3b4d5f1112f0f51fa93ff02a792c65a44df7b6dad17bd51f26"
    }
  },
  {
    "ts": null,
    "headline": "Biogen : Q1 2025 Biogen Earnings Presentation",
    "summary": "May 1, 2025 FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE ...",
    "url": "https://finnhub.io/api/news?id=88b0ab958cf229538cb25488ee65f7a4de235811392584baf09b369d99f37d8a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746082148,
      "headline": "Biogen : Q1 2025 Biogen Earnings Presentation",
      "id": 134170401,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "May 1, 2025 FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE ...",
      "url": "https://finnhub.io/api/news?id=88b0ab958cf229538cb25488ee65f7a4de235811392584baf09b369d99f37d8a"
    }
  },
  {
    "ts": null,
    "headline": "Biogen : Q125 Earnings Presentation FINAL",
    "summary": "May 1, 2025 FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE ...",
    "url": "https://finnhub.io/api/news?id=cbc8f64a07eb58e1e6a7e4d9042a524a36dc30e5c54a98e71b612e0c4eabbcf8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746082148,
      "headline": "Biogen : Q125 Earnings Presentation FINAL",
      "id": 134170399,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "May 1, 2025 FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE ...",
      "url": "https://finnhub.io/api/news?id=cbc8f64a07eb58e1e6a7e4d9042a524a36dc30e5c54a98e71b612e0c4eabbcf8"
    }
  },
  {
    "ts": null,
    "headline": "Biogen beats quarterly profit estimates on strong demand for rare disease drugs",
    "summary": "Biogen beat first-quarterprofit and revenue expectations on Thursday, as strong demandfor its rare disease drugs helped offset declining sales of itsmultiple sclerosis drugs. The...",
    "url": "https://finnhub.io/api/news?id=57da73229c5561ea6fd90f4bf9e4d22ab534210acd7721ecc6e8f921b1f8ed6f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746081920,
      "headline": "Biogen beats quarterly profit estimates on strong demand for rare disease drugs",
      "id": 134170397,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Biogen beat first-quarterprofit and revenue expectations on Thursday, as strong demandfor its rare disease drugs helped offset declining sales of itsmultiple sclerosis drugs. The...",
      "url": "https://finnhub.io/api/news?id=57da73229c5561ea6fd90f4bf9e4d22ab534210acd7721ecc6e8f921b1f8ed6f"
    }
  }
]